论文部分内容阅读
目的观察布地奈德福莫特罗粉吸入剂治疗青少年变应性鼻炎合并哮喘的疗效。方法选取2012年1月-2013年12月45例青少年变应性鼻炎合并哮喘患者,完全随机化分组分成一般治疗组、布地奈德组、布地奈德福莫特罗组,每组15例,另设体检健康者15例为对照组。一般治疗组采用氨茶碱等一般治疗,布地奈德组在一般治疗基础上,给予布地奈德气雾剂100~200μg/(吸·次),2次/d;布地奈德福莫特罗组为一般治疗+布地奈德福莫特罗粉吸入剂,1吸/次,2次/d,其中吸入剂中含布地奈德含量160μg,福莫特罗4.5μg。连续用药4周后,停药4周进行一氧化氮(NO)呼出气检查。结果一般治疗组、布地奈德组、布地奈德福莫特罗组NO呼出气治疗前后自身相比,差异有统计学意义(P<0.05);3组治疗前后与对照组比较差异均有统计学意义(P<0.05);布地奈德组、布地奈德福莫特罗组NO呼出气治疗后相比差异有统计学意义(P<0.05)。结论布地奈德福莫特罗吸入剂治疗青少年变应性鼻炎合并哮喘患者在改善NO呼出气方面效果良好。
Objective To observe the efficacy of budesonide formoterol powder inhalation in the treatment of juvenile allergic rhinitis with asthma. Methods From January 2012 to December 2013, 45 adolescents with allergic rhinitis and asthma were randomly divided into general treatment group, budesonide group and budesonide formoterol group, 15 cases in each group, Another set of physical examination of 15 cases of healthy control group. The general treatment group with aminophylline and other general treatment, budesonide group on the basis of general treatment, given budesonide aerosol 100 ~ 200μg / (suction · times), 2 times / d; budesonide formoterol Group for the general treatment + budesonide formoterol powder inhaler, 1 / times, 2 times / d, inhaled budesonide content of 160μg, formoterol 4.5μg. After 4 weeks of continuous treatment, withdrawal of nitric oxide (NO) expired gas for 4 weeks was examined. Results Compared with the control group, the difference was statistically significant (P <0.05) before and after NO exhaled breath in the treatment group, the budesonide group and the budesonide formoterol group. There were statistical differences between the three groups before and after treatment with the control group (P <0.05). There were significant differences in NO exhaled breath between budesonide group and budesonide formoterol group (P <0.05). Conclusion The efficacy of budesonide formoterol inhaler in the treatment of adolescent allergic rhinitis with asthma is good in improving NO exhaled breath.